U.S. Markets close in 3 hrs 58 mins
  • S&P 500

    4,344.14
    -88.85 (-2.00%)
     
  • Dow 30

    33,943.83
    -641.05 (-1.85%)
     
  • Nasdaq

    14,668.92
    -375.05 (-2.49%)
     
  • Russell 2000

    2,175.87
    -61.00 (-2.73%)
     
  • Crude Oil

    70.75
    -1.22 (-1.70%)
     
  • Gold

    1,762.40
    +11.00 (+0.63%)
     
  • Silver

    22.36
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1733
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    1.3210
    -0.0490 (-3.58%)
     
  • Vix

    25.61
    +4.80 (+23.07%)
     
  • GBP/USD

    1.3654
    -0.0084 (-0.6103%)
     
  • USD/JPY

    109.4590
    -0.4360 (-0.3967%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,097.02
    -37.36 (-3.29%)
     
  • FTSE 100

    6,908.48
    -55.16 (-0.79%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Sorrento Therapeutics on COVID-19 Therapy Competition: "Our Antibody Is Better Than Theirs"

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) discuss the company's therapeutic antibodies to treat COVID-19, the disease caused by the novel coronavirus. Mark Brunswick, senior vice president of regulatory affairs at Sorrento, claims that the company's antibodies are better than the ones being developed by Eli Lilly (NYSE: LLY) and Regeneron (NASDAQ: REGN). Henry Ji, chairman, president, and CEO of Sorrento, explains how the company engineered the antibodies to remove the likelihood of antibody-dependent enhancement (ADE), a phenomenon in which the antibody binding to the virus enhances the entry of the virus into the cell.